



## Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 24, 2023

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 24, 2023-- [Exelixis, Inc.](#) (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.

To access the webcast link, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 888-338-9509 (domestic) or 412-902-4281 (international) and ask to be joined into the Exelixis conference call to participate by phone.

A telephone replay will be available until 8:00 p.m. ET on February 9, 2023. Access numbers for the telephone replay are: 877-344-7529 (domestic) and 412-317-0088 (international); the passcode is 7374267. A webcast replay will also be archived on [www.exelixis.com](http://www.exelixis.com) for one year.

### About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX<sup>®</sup> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit [www.exelixis.com](http://www.exelixis.com), follow [@ExelixisInc](#) on Twitter, like [Exelixis, Inc.](#) on Facebook and follow [Exelixis](#) on LinkedIn.

*Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.*

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230124006010/en/): <https://www.businesswire.com/news/home/20230124006010/en/>

### Investors Contact:

Susan Hubbard  
Executive Vice President,  
Public Affairs & Investor Relations  
Exelixis, Inc.  
650-837-8194  
[shubbard@exelixis.com](mailto:shubbard@exelixis.com)

### Media Contact:

Hal Mackins  
For Exelixis, Inc.  
415-994-0040  
[hal@torchcommunications.com](mailto:hal@torchcommunications.com)

Source: Exelixis, Inc.